The Union health ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, that would require antimicrobial manufacturers to obtain central permission before applying to a state for a manufacturing licence. The draft notification, G.S.R. 983(E) dated November 6, proposes to bring antimicrobials under the definition of "new drug," the ministry said in a statement on Thursday.

Under the proposal, manufacturers would need approval from the Central Licensing Authority (CLA) before seeking a manufacturing licence from the concerned state licensing authority (SLA). The ministry said the move is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products.

At present, state authorities grant manufacturing licences for these products. According to persons aware of the matter, the amendment was prompted by concerns that some products were cleared without adequate regulatory scrutiny, including studies such as bioavailability/bioequivalence and stability studies. The ministry said substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance (AMR), posing risks to patient safety.

A senior health ministry official, who asked not to be named, said the change will apply prospectively. Licences already granted will remain valid, and existing licence holders will not have to reapply. The official described the proposal as an additional regulatory safeguard against AMR and part of the government's broader efforts to promote responsible use of antimicrobials and safeguard patient safety. The draft has been issued to invite objections and suggestions from stakeholders and the public within 30 days before the central government considers it for finalisation.